Aurobindo Pharma completes transfer of domestic branded generics business to subsidiary Auropharm

Aurobindo Pharma told the exchanges it has completed the transfer of its domestic branded generic pharmaceutical formulations business to Auropharm Limited (formerly Auro Pharma Limited), a wholly owned subsidiary. The move follows the Business Transfer Agreement the company disclosed in its letter dated 6 April 2026. The company said the terms of that agreement are now complete.

Per the filing, the business was transferred as a going concern on a slump sale basis, and is now being undertaken in Auropharm Limited with effect from 1 July 2026. Because Auropharm is a wholly owned subsidiary, the business stays within the Aurobindo group; the change is one of legal housing rather than a sale to an outside party.

The filing marks the closing of a step Aurobindo signalled in April — moving its domestic branded generics into a separate corporate entity. It does not disclose the consideration, the financials of the business, or the strategic rationale, so holders learn only that the reorganisation is now effective.